Articles tagged with Cancer Cells
Researchers at the University of Chicago Medical Center have created a new screening tool for ovarian cancer that can rapidly test compounds to block metastasis. The three-dimensional cell-culture system mimics human tissue and has identified small molecules that inhibit adhesion and invasion.
Researchers have visualized the molecular process behind a protein that punches holes into cancer cells, using edible oyster mushrooms as inspiration. The findings could lead to new treatments for autoimmune diseases, malaria, and pests in agriculture, while also introducing a powerful tool against infectious diseases.
Researchers discovered that lab-grown cells undergo rapid changes within three days of adaptation to their new environment. This finding affects the interpretation of past studies and provides clues for improving cell cultures.
Scientists at TU Dresden have presented a novel method, real-time deformability cytometry (RT-DC), to mechanically screen large populations of cells quickly and accurately. This technology enables the continuous, on-the-fly mechanical screening of hundreds of cells per second.
Fox Chase researchers discovered that pancreatic cancer cells sidestep chemotherapy by hijacking the vitamin D receptor, a key mechanism driving chemotherapeutic effectiveness against pancreatic cancer. The findings raise hopes for developing new treatments that can selectively kill cancer cells while leaving healthy cells unharmed.
Researchers at UMD have developed a technology platform for creating targeted drug and vaccine delivery vehicles using customized soap bubbles. The technology can produce 1,000 doses of vaccines in just 72 hours.
Researchers used game theory to model cooperation among cancer cells, finding that free-riding cells can outcompete producing ones. Computer simulations and experiments with pancreatic cancer cells validated the predictions, suggesting new insight into cancer dynamics.
A green tea compound may trigger a process in the mitochondria that leads to cell death, reducing cancer cell defenses. Researchers found EGCG selectively targets sirtuin 3 in cancer cells, causing oxidative stress and programmed cell death.
A new protein-based therapy has been developed to target drug-resistant leukemia cells, with promising results in mouse models and potentially amplifying the potency of standard treatment options. The fusion protein CD19L-sTRAIL selectively binds and delivers a 'death signal' to leukemia cells.
Researchers at the University of Copenhagen have discovered that Ras protein misregulation is linked to cell shape. By targeting changes in membrane curvature, they hope to develop new ways to diagnose and treat cancers.
Researchers have found that cooperation between cancer cells leads to the evolution of resistance and relapses after therapy. A new treatment approach involves genetically modifying cancer cells to remove growth factor-producing genes, potentially eliminating tumor heterogeneity.
Researchers have discovered that highly efficient DNA methyl transferase 1 (DNMT1) enzymes found in cancer cells are responsible for the abnormal turning on and off of genes. The findings suggest that a drug targeting this enzyme may be beneficial for cancer treatment, potentially reducing cancer relapse.
Researchers propose a novel approach to cancer therapy by subtly hardening cancer cells to prevent metastasis. They've identified a compound, 4-HAP, that shows promise in fighting pancreatic cancer.
A new study identifies pyruvate carboxylase as a key metabolic enzyme that drives proliferation in non-small cell lung cancer. Elevated PC expression was found in cancerous tissues and decreased growth rates when PC was reduced or inhibited.
A new statistical method for RNA-seq analysis has identified and corrected for hidden structure between cells, revealing new subtypes that may have distinct functions. This breakthrough allows researchers to create more accurate gene-expression profiles and explore cell types in cancers and diseases.
The Damon Runyon-Rachleff Innovation Award funds novel approaches to fighting cancer, enabling exceptionally creative thinkers to develop high-risk/high-reward ideas that lack preliminary data. The awardees have the potential to significantly impact cancer prevention, diagnosis, and treatment.
Researchers have discovered that targeting a cell 'survival' protein could help treat some lymphomas, including those cancers with genetic defects that make them resistant to many existing therapies. Removing MCL-1 causes the death and elimination of lymphoma cells that had become resistant to conventional cancer treatments.
Researchers at UCSB's Reich Group have developed a method for spatially and temporally controlling the release of proteins inside cells using near-infrared laser-activated nanocarriers. This technology allows for targeted protein delivery, enabling new avenues for basic research and therapeutic applications.
Researchers developed a drug delivery technique using graphene strips to sequentially deliver two anticancer drugs, TRAIL and doxorubicin, targeting distinct parts of the cell. The technique significantly improved treatment efficacy compared to isolated therapies in mouse models targeting human lung cancer tumors.
Researchers have identified a novel cellular biomarker that can determine if a tumor has a potentially lethal mutation in the p53 protein, which is often referred to as the 'guardian of the genome'. The new biomarker can be used to assess p53 status in as little as 15 minutes.
Researchers developed a system to selectively insert compounds into cancer cells, identifying malignant tissues for precise surgery. The technology uses near-infrared light to kill remaining cancer cells, promising a more accurate and effective approach to cancer surgeries.
Scientists discovered a small molecule, 6-thiodG, that can stop cancer cell growth and shrink tumors in mice. The compound works by disrupting the normal way cells maintain telomere length, triggering cell death.
Researchers at Case Western Reserve University identified a way to increase the presence of the 53BP1 protein, which weakens cancer cells and makes them more susceptible to radiation and chemotherapy. The breakthrough could lead to improved cancer treatment outcomes if supported by animal model tests.
Researchers have found a new potential target for liver cancer treatment in the protein TREM-1, which accelerates chronic inflammation. Studies suggest that blocking TREM-1 can block the conversion of healthy cells to cancerous ones and even stop progression of existing cancer.
Researchers found that lung cancer cells sever protein ties, allowing them to break loose and spread. Targeting this process could stop lung cancer from spreading by keeping cells stuck together.
Penn researchers developed mathematical models of collagen matrix stiffness, providing insights into fibrosis, cirrhosis, and certain cancers. The models show that nonlinear elasticity can arise from the ECM's fibrous structure, allowing for long-range force transmission and bridging formation.
A study led by St. Jude Children's Research Hospital scientists has identified the population of white blood cells that tumors use to enhance growth and suppress the disease-fighting immune system. Monocytes are primarily responsible for T cell suppression around tumors.
Scientists develop novel class of molecules that could revolutionize immunotherapy for cancer and other diseases. The synthetic antibody mimics, or SyAMs, are smaller than current biologics and may avoid their risks.
A team of researchers has discovered a previously unknown form of multidrug resistance in cancer cells, known as inducible drug glucuronidation. By understanding this chemical pathway, scientists may be able to develop new treatments that can overcome this resistance and improve patient outcomes.
Researchers at Yale University have developed synthetic antibody mimics (SyAMs) that target disease cells and stimulate immune responses, offering potential for treating prostate cancer and other diseases.
Researchers found that infant cells must undergo a developmental process involving specific genes before they can participate in group interactions. The study identified the Lsd1 gene as crucial for ovarian follicle progenitor cells to mature at their normal rate.
Researchers found that adding thymine to normal cells stimulates gene production and causes them to multiply. This could lead to a treatment supplement to boost healthy cell production during chemotherapy, while minimizing side effects.
Researchers at the Buck Institute discovered that senescent cells secrete PDGF-AA, which accelerates wound closure and heals wounds normally. This finding suggests that cellular senescence may play a beneficial role in human health throughout the lifespan.
Researchers at the University of Manchester discovered a molecular 'tag team' controlling cell division in yeast cells. This relay system ensures proper regulation of mitotic exit, a critical step in preventing abnormal growth and cancer development.
Scientists at IRB Barcelona have identified two derivatives of borrelidin that completely remove the parasite load from mice and confer immunological memory to fight future infections. These compounds act on the protein production machinery of the parasite, making them efficient in all phases of infection.
Scientists at MCW found a link between sleep loss and cell injury, particularly in the liver, lung, and small intestine. Recovery sleep from deprivation restores balance and decreases cell injury, elucidating previous research on sleep abnormalities as risk factors for diseases like cardiovascular disease and cancer.
Researchers identified a critical pathway that enables cancer cells to survive despite DNA errors, relying on the PKCƐ signal pathway. Disrupting this pathway could trigger cancer cells to self-destruct, offering a new strategy to beat the disease.
In an early-phase clinical trial, a new type of cancer therapy targeting the IDH2 gene produced dramatic results in patients with advanced leukemia. The study found that AG-221 blocked the mutated protein, allowing immature white blood cells to develop normally and leading to complete or partial remissions.
New immunotherapy treatments aim to enable the body's natural defenses to recognize and destroy malignant cells. Studies present promising early data that encourage long-term outcomes among patients who have not responded to other therapies, including checkpoint inhibitors and drugs targeting the PD-1 pathway.
Researchers found that cancer cells and fibroblasts collaborate to invade the basement membrane, a process that begins long before the actual movement of cancer cells. CAFs secrete more proteases and matrix proteins than normal fibroblasts, which helps them remodel the basement membrane.
Researchers demonstrate that the innate immune system recognizes weaker cells and activates programmed cell death, eliminating them in a process called cell competition. This phenomenon has implications for cancer research and early disease detection.
Researchers at the University of Adelaide have discovered that cancer cells with chromosomal instability are vulnerable to mild metabolic disruption, making them a potential target for new therapy. The study's findings suggest that targeting these unstable cells could lead to more effective treatments with fewer side effects.
Researchers found high-dose interleukin-2 to be effective in metastatic renal cell cancer patients pre-treated with VEGF-targeted agents, achieving durable complete responses in a selected population. The therapy's efficacy and safety were confirmed, offering an alternative treatment option for carefully selected patients.
Researchers at MIT have developed a load driver device that can reduce unpredictability in biological circuits, allowing for robust and predictable behavior. This breakthrough could lead to applications such as biosensing and glucose monitoring for diabetic patients.
Researchers mapped p53 binding sites in human cancer and normal cells, finding the protein binds selectively to repeat sequences in cancer cells. This suggests p53's role in maintaining genomic stability and tumor suppression is context-dependent.
Researchers established induced pluripotent stem (iPS) cells from Werner syndrome fibroblasts, which can be used for drug discovery and gene therapy. The iPS cells have recovered telomeric abnormalities and similar expression levels of aging-related genes as normal iPS cells.
Research reveals Chlamydia trachomatis breaks down protective protein p53, allowing cells to mutate and develop into cancer. The bacterium exploits this mechanism to survive within host cells, posing a potential risk for cancer development.
Researchers have solved a decades-old mystery by uncovering the formation of massive DNA molecules, dubbed 'neochromosomes', in some tumours. These giant chromosomes are formed through catastrophic chromosomal shattering and genetic amplification, ensuring the cancer's survival.
Researchers have determined the structure of an ABC transporter complex, enabling targeted therapeutic approaches to combat antibiotic resistance and cancer cell defense. The study's breakthrough has significant implications for treating cystic fibrosis, bacterial infections, and cancer.
Researchers found a new strategy and potential drug to target faulty Ras protein, which causes cancer by producing excess signals. This breakthrough offers opportunities for developing new treatments that exploit the discovery without harming healthy cells.
Researchers have successfully triggered the self-destruct process in lung cancer cells, paving the way for a new treatment approach that leaves healthy cells unharmed. The breakthrough was achieved using a combination of two drugs, TRAIL and a CDK9 inhibitor, which altered the molecular switches in the cell suicide process.
Melbourne researchers have discovered the three-dimensional structure of a key cell death protein called Bak and revealed how it causes cell death. The study offers new targets for treating diseases such as lupus, cancers, and neurodegenerative disorders.
Two new studies from Johns Hopkins shed light on how complex cells detect and respond to minute differences in chemical concentrations. Cells use their internal 'skeleton' to influence gradient detection and movement, with implications for development, immune response, wound healing, and cancer metastasis.
Bio-engineers at ETH Zurich have created a biological circuit that controls sensor components using internal timers, enabling precise signal transmission. This breakthrough could lead to reprogramming cancer cells and creating complex bio-computers to detect and kill cancer cells.
The study identifies tiny differences in protein sequences between cancer cells and healthy tissue, enabling the creation of personalized vaccines. The research aims to improve treatment outcomes for patients with ovarian cancer, which often responds well to surgery and chemotherapy but returns lethally within a year or two.
A team of scientists has uncovered a new mechanism controlling actin-rich protrusions that aid in cell migration, a process essential for development, wound healing, and immunological responses. GMF protein plays a key role in regulating these protrusions.
Researchers at Imperial College London have developed a new cancer drug, DTP3, that selectively kills multiple myeloma cells without causing toxicity. The drug works by stopping the NF-kB pathway, which allows cancer cells to multiply, and has been awarded funding for clinical trials in patients with multiple myeloma.
Researchers at North Carolina State University have developed a DNA-based drug delivery system that targets cancer cells using nano-cocoons made of DNA. The system uses self-assembling DNA techniques and specifically delivers anticancer drugs to cancer cells, releasing them quickly once inside.
Researchers discovered that chromosome rearrangements can induce additional errors in cell division, leading to genetic instability. The study found that misplaced DNA segments can lead to the formation of extra cohesion sites, causing abnormal chromosome stretching during cell division.
Researchers found that nuclear factor kappa B (NF-kB) enables cancer cells to evade the immune system by suppressing genes that inhibit the immune response. Inhibiting NF-kB may make tumor cells more vulnerable to elimination by the immune system.